In Vitro Production of Endomysial Antibodies in Cultured Duodenal Mucosa From Patients With Celiac Disease

Vogelsang, Harald; Schwarzenhofer, Maria; Granditsch, G; Oberhuber, Georg

doi:10.1111/j.1572-0241.1999.01014.x

Cited by 20 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The full texts of the remaining 36 studies were evaluated in detail, and 21 studies were excluded for being review articles, letters to editors, or case reports. Finally, 15 relevant studies were included in our systematic review and meta-analysis (12,13,15,18,(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36). No study was excluded because of insufficient data for calculating sensitivity and specificity.…”

Section: Resultsmentioning

confidence: 99%

In Vitro Gluten Challenge Test for Celiac Disease Diagnosis

Khalesi¹,

Jafari

Kiani

et al. 2016

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

In Vitro Gluten Challenge Test for Celiac Disease Diagnosis

Khalesi¹,

Jafari

Kiani

et al. 2016

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

“…In the last 20 years different assays have been used: measurement in faeces [23] or in intestinal fluids [24], search in supernatants of cultured biopsy fragments [11][12][13][14][15][16][17] or detection in the same biopsies of deposited antibodies [16], or expression in phage libraries of RNA, obtained from biopsies, coding for the antibodies [6,22]. Detection of anti-endomysium antibodies (EMA) and anti-TG2 IgA antibodies in faecal supernatants from CD patients was determined to be unreliable as a diagnostic test [25].…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have reported that when specimens of duodenal mucosa are cultured for 24-48 h in medium alone and with peptic-tryptic digest of gliadin (PTG) [11,12] or with peptide 31-43 (P31-43) [13,14], there is a production of anti-endomysial antibodies in organ culture supernatants in CD patients, but not in controls.…”

Section: Introductionmentioning

confidence: 99%

Intestinal anti-tissue transglutaminase antibodies in potential coeliac disease

Tosco

Aitoro

Auricchio

et al. 2012

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryAnti-tissue transglutaminase 2 (anti-TG2) antibodies are present in the serum of the great majority of untreated coeliac disease (CD) patients. They are produced and deposited in the small intestinal mucosa. Potential CD patients present serum anti-TG2 antibodies higher than cut-off, but a normal duodenal mucosa where mucosal deposits of anti-TG2 are not always detectable. The aim of our work was to investigate the presence of anti-TG2 intestinal antibodies in patients with potential CD, and identify the most sensitive test to detect them. Twelve active CD patients, 28 potential CD patients and 39 non-CD controls were enrolled. Biopsy fragments from all patients were analysed by double immunofluorescence to detect mucosal deposits of anti-TG2 antibodies. Fragments from the same subjects were also cultured for 24 h with medium in the presence or absence of gliadin peptides. Anti-TG2 autoantibodies secreted into supernatants were measured by enzyme-linked immunosorbent assay. All active CD, 68% of potential CD patients and 20% of non-CD controls showed mucosal deposits of immunoglobulin (Ig)A anti-TG2; at the same time 100, 96 and 8% of active CD, potential CD and non-CD control patients secreted these antibodies in culture supernatants, respectively. Our data showed that, to detect intestinal anti-TG2 antibodies, the measurement of antibodies secreted into culture supernatants has higher sensitivity and specificity (97·5 and 92·3%, respectively) than the detection of mucosal deposits (77·5 and 80·0%, respectively). The measurement of intestinal anti-TG2 antibodies may prove useful in clinical practice to predict evolution towards mucosal atrophy in potential coeliac patients and identify patients with gluten sensitivity.

show abstract

“…Ileal biopsy specimens were collected and cultured for 6 h in 1 ml medium at 95% O 2 in a pressurized incubation chamber before and after treatment [35]. The tissue culture medium was composed of 75% Trowell’s T8 medium and 25% NCTC medium supplemented with 250 U/ml penicillin, 250 µg/ml streptomycin, and 5 m M L -glutamine (all purchased from Life Technologies/Gibco BRL, Paisley, UK).…”

Section: Methodsmentioning

confidence: 99%

An Open-Label Pilot Study of Granulocyte Colony-Stimulating Factor for the Treatment of Severe Endoscopic Postoperative Recurrence in Crohn’s Disease

Dejaco¹,

Lichtenberger²,

Miehsler³

et al. 2003

Digestion

Self Cite

View full text Add to dashboard Cite

Background/Aim: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) promoted healing of Crohn’s disease (CD)-like intestinal lesions in chronic granulomatous disease and glycogen storage disease Ib, both characterized by defective neutrophil functions. We performed a prospective, open-label pilot study with rhG-CSF for the treatment of CD. Patients andMethods: Five patients with clinically inactive CD, but with severe endoscopic ileitis within 1 year after intestinal resection and ileocolonic anastomosis, received 300 µg of rhG-CSF (Filgrastim; Neupogen^®) subcutaneously, three times weekly for a total of 12 weeks. Safety was evaluated by assessment of clinical and laboratory data and disease activity. The primary parameter of efficacy was complete mucosal healing, as defined by the Rutgeerts score. Anti-inflammatory mediators were repeatedly measured during treatment. Results: All patients completed the protocol in clinical remission. In 1 subject transient headache resolved after halving the rhG-CSF dosage. Complete mucosal healing was observed in 2 patients: in 1 patient after 12 weeks of therapy and in 1 patient 9 months after treatment cessation. In a single patient, closure of an anovaginal and of a perianal fistula was noted. Neutrophil counts and interleukin-1 receptor antagonist and soluble tumor necrosis factor receptor p55 and p75 levels were found to be increased during drug administration. Conclusion: rhG-CSF seems to be safe, well tolerated, and might provide efficacy in CD.

show abstract

In Vitro Production of Endomysial Antibodies in Cultured Duodenal Mucosa From Patients With Celiac Disease

Abstract: EMAs seem to be produced in the small bowel mucosa of celiac patients, but not in other tissues such as gastric mucosa. The production of EMAs could not be initiated under standard in vitro conditions and therefore, such as in vitro challenge cannot be used for diagnostic purposes.

Cited by 20 publications

References 15 publications

In Vitro Gluten Challenge Test for Celiac Disease Diagnosis

In Vitro Gluten Challenge Test for Celiac Disease Diagnosis

Intestinal anti-tissue transglutaminase antibodies in potential coeliac disease

An Open-Label Pilot Study of Granulocyte Colony-Stimulating Factor for the Treatment of Severe Endoscopic Postoperative Recurrence in Crohn’s Disease

Contact Info

Product

Resources

About